Remove Bicuspid/Mitral Remove Stenosis Remove Tricuspid
article thumbnail

FDA Advisory Committee Votes in Favor of Abbott’s First-of-its-kind Triclip System to Treat People with a Leaky Tricuspid Heart Valve

DAIC

Food and Drug Administration ( FDA ) confirmed 13 to 1, with 0 abstention that the benefits of Abbott's TriClip™ transcatheter edge-to-edge repair (TEER) system outweighed the risks for the treatment of people with tricuspid regurgitation (TR). On the final question of the benefit of TriClip versus the risk, the vote was 13 to 1 in favor.

Tricuspid 102
article thumbnail

Abbott Announces FDA Approval of First-of-its-kind Device to Repair Leaky Tricuspid Heart Valve, TriClip

DAIC

Food and Drug Administration (FDA) approval of its TriClip, a first-of-its-kind device to repair leaky tricuspid heart valve, for which more than 1.6 are affected by tricuspid regurgitation, 1 which can severely impact quality of life. Abbott has announced U.S million people in the U.S. are estimated to be affected. the Roger L.

Tricuspid 105
article thumbnail

Tricuspid regurgitation: Frequency, clinical presentation, management and outcome among patients with severe left?sided valvular heart disease in Europe. Insights from the ESC?EORP Valvular Heart Disease II survey

European Journal of Heart Failure

Tricuspid regurgitation (TR): frequency, clinical presentation, management and outcome among patients with severe left-sided valvular heart disease in Europe. ESC-EORP, European Society of Cardiology-EURObservational Research Programme; TV, tricuspid valve.

article thumbnail

Progression of aortic stenosis after an acute myocardial infarction

Open Heart

Background Myocardial infarction (MI) has been shown to induce fibrotic remodelling of the mitral and tricuspid valves. It is unknown whether MI also induces pathological remodelling of the aortic valve and alters aortic stenosis (AS) progression.

article thumbnail

Artificial intelligence-enabled phenotyping of patients with severe aortic stenosis: on the recovery of extra-aortic valve cardiac damage after transcatheter aortic valve replacement

Open Heart

Objective A novel artificial intelligence-based phenotyping approach to stratify patients with severe aortic stenosis (AS) prior to transcatheter aortic valve replacement (TAVR) has been proposed, based on echocardiographic and haemodynamic data. ±15.8 ±15.1 mm Hg, p value: 0.0079).

article thumbnail

SAVR’s Value in the TAVR Era

CardiacWire

Much of these SAVR declines occurred in patients with tricuspid aortic valves (from 84.5% to 55% of total SAVRs), while SAVR ratios increased among patients with bicuspid aortic valves (from 15.5% That’s a positive trend given that <80yr SAVR patients with bicuspid aortic valves also had better-than-expected mortality rates.

TAVR 69
article thumbnail

Cardiovascular Research Foundation, CRF, Introduces New York Valves: The Structural Heart Summit

DAIC

Transcatheter valve therapy has evolved from a novel treatment for the sickest patients to become the standard of care for many with aortic stenosis. The rapid adoption of transcatheter mitral and tricuspid therapies has also transformed the treatment landscape, expanding options for patients with structural heart disease.